I am with you on your beliefs. I am just as wounded but still see the big picture for Covid. I see the CD-12 trial was just to slow and standard of care improved so much that it made it difficult to show major improvement needed. Not that Leronlimab wasn’t the best drug for critical and still will be. We probably are the very best but size of trial hindered us. Trial design also limited us and that’s a terrible issue to live with. Unfortunately we have to live with it. Time more than design is what really screwed us the most. We have many other indications to look forward to but Covid could be our bread and butter for quickest revenue unless a BTD were to be shown for cancer. There is that chance.
As for market impact for just critical Covid and our future impact there. It’s not as much as we would hope even with a future EUA for Critical. As the standard of care and vaccine impact consistently improves we will have a smaller and smaller impact because the numbers of patients will constantly be reduced over time.
The time we need now is a much improved speedy investigational trial for Long Haulers with great success. So we can have a even quicker phase 3 LH trial. Hopefully before big Pharma again beats us to the finish line. That’s the fear for me. If we can place in the top 3 and hopefully the first to apply for EUA for Long Haulers. This will be the most important timely trial to help us acquire a EUA for a large indication of Covid.
We somehow missed the boat on all the other indications because piecemeal medicine being used like Dr. Patterson said would happen. It comes down to the first to finish with some minor improvements is the most likely to get approved. We were far to slow. I hope the lesson is learned and that we waist no time with CD-16 and the Long Hauler trials. Time is of the essence in order to have the impact necessary to show the best or necessary improvement needed for an approval. Being the first top 1-3 drugs approved for LH becomes tougher as more drugs will apply and trial for LH. We may be opening the door but others will follow.
Long Haulers is a huge market now and going forward. It’s really the golden egg for our investment. Up to 30% of all covid infected is a very large group. It will fund all the trials we want to run for years. Covid is not going away and 30-50% of people will not use a vaccine. They just don’t believe in them or have some religious or even political reason not to be vaccinated. It’s sad but true. These people will keep us all wearing masks for who knows how long. Our only real hope is that those that don’t vaccinate do catch covid and we become safer with heard immunity with the combination of both vaccines and covid infection. We are now realized as a never ending endemic. Leronlimab will get there. But time is everything now.
As for market impact for just critical Covid and our future impact there. It’s not as much as we would hope even with a future EUA for Critical. As the standard of care and vaccine impact consistently improves we will have a smaller and smaller impact because the numbers of patients will constantly be reduced over time.
The time we need now is a much improved speedy investigational trial for Long Haulers with great success. So we can have a even quicker phase 3 LH trial. Hopefully before big Pharma again beats us to the finish line. That’s the fear for me. If we can place in the top 3 and hopefully the first to apply for EUA for Long Haulers. This will be the most important timely trial to help us acquire a EUA for a large indication of Covid.
We somehow missed the boat on all the other indications because piecemeal medicine being used like Dr. Patterson said would happen. It comes down to the first to finish with some minor improvements is the most likely to get approved. We were far to slow. I hope the lesson is learned and that we waist no time with CD-16 and the Long Hauler trials. Time is of the essence in order to have the impact necessary to show the best or necessary improvement needed for an approval. Being the first top 1-3 drugs approved for LH becomes tougher as more drugs will apply and trial for LH. We may be opening the door but others will follow.
Long Haulers is a huge market now and going forward. It’s really the golden egg for our investment. Up to 30% of all covid infected is a very large group. It will fund all the trials we want to run for years. Covid is not going away and 30-50% of people will not use a vaccine. They just don’t believe in them or have some religious or even political reason not to be vaccinated. It’s sad but true. These people will keep us all wearing masks for who knows how long. Our only real hope is that those that don’t vaccinate do catch covid and we become safer with heard immunity with the combination of both vaccines and covid infection. We are now realized as a never ending endemic. Leronlimab will get there. But time is everything now.
4
